Veradigm Inc. – OTC:MDRX
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 5 hours
Veradigm stock price monthly change
-4.06%
month
Veradigm stock price quarterly change
-4.06%
quarter
Veradigm stock price yearly change
-9.22%
year
Veradigm key metrics
Market Cap | 1.02B |
Enterprise value | 1.13B |
P/E | 14.99 |
EV/Sales | 1.34 |
EV/EBITDA | 6.91 |
Price/Sales | 1.67 |
Price/Book | 1.19 |
PEG ratio | -0.19 |
EPS | N/A |
Revenue | N/A |
EBITDA | N/A |
Income | N/A |
Revenue Q/Q | -100% |
Revenue Y/Y | -100% |
Profit margin | 7.24% |
Oper. margin | 8.07% |
Gross margin | 48.42% |
EBIT margin | 8.07% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeVeradigm stock price history
Veradigm stock forecast
Veradigm financial statements
| Dec 2022 | 0 | 0 | |
|---|---|---|---|
| Mar 2023 | 0 | 0 | |
| Jun 2023 | 0 | 0 | |
| Sep 2023 | 0 | 0 |
| 2025 | 676.68M | 43.3M | 6.4% |
|---|---|---|---|
| 2026 | 710.4M | 59.8M | 8.42% |
Analysts Price target
Financials & Ratios estimates
| 2022-11-03 | 0.19 | 0.23 |
|---|---|---|
| 2023-03-01 | 0.23 | 0.72 |
| Sep 2022 | 1690700000 | 513.7M | 30.38% |
|---|---|---|---|
| Mar 2023 | 0 | 0 | |
| Jun 2023 | 0 | 0 | |
| Sep 2023 | 0 | 0 |
| Dec 2022 | 0 | 0 | 0 |
|---|---|---|---|
| Mar 2023 | 0 | 0 | 0 |
| Jun 2023 | 0 | 0 | 0 |
| Sep 2023 | 0 | 0 | 0 |
Veradigm alternative data
| Aug 2023 | 8,000 |
|---|---|
| Sep 2023 | 8,000 |
| Oct 2023 | 8,000 |
| Nov 2023 | 8,000 |
| Dec 2023 | 8,000 |
| Jan 2024 | 8,000 |
| Feb 2024 | 8,000 |
| Mar 2024 | 8,000 |
| Apr 2024 | 8,000 |
| May 2024 | 8,000 |
| Jun 2024 | 8,000 |
| Jul 2024 | 8,000 |
Veradigm other data
89.78%
+6.31%
of MDRX is owned by hedge funds
220
-12
106.57M
-9.19M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Feb 2024 | 6225000 | 0 |
| Mar 2024 | 3997875 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | STONEHILL CAPITAL MANAGEMENT LLC 10 percent owner | Common Stock, par value $0.01 per share | 2,398,725 | $6 | $14,392,350 | ||
Purchase | STONEHILL CAPITAL MANAGEMENT LLC 10 percent owner | Common Stock, par value $0.01 per share | 1,599,150 | $6 | $9,594,900 | ||
Purchase | STONEHILL CAPITAL MANAGEMENT LLC 10 percent owner | Common Stock, par value $0.01 per share | 278,250 | $6.09 | $1,694,543 | ||
Purchase | STONEHILL CAPITAL MANAGEMENT LLC 10 percent owner | Common Stock, par value $0.01 per share | 246,750 | $6.09 | $1,502,708 | ||
Purchase | STONEHILL CAPITAL MANAGEMENT LLC 10 percent owner | Common Stock, par value $0.01 per share | 3,021,000 | $6.81 | $20,573,010 | ||
Purchase | STONEHILL CAPITAL MANAGEMENT LLC 10 percent owner | Common Stock, par value $0.01 per share | 2,679,000 | $6.81 | $18,243,990 | ||
Sale | POULTON RICHARD J. director, officer: CEO | Common Stock | 10,000 | $17.33 | $173,300 | ||
Sale | POULTON RICHARD J. director, officer: CEO | Common Stock | 10,000 | $17.38 | $173,840 | ||
Sale | VAKHARIA TEJAL officer: SVP Gene.. | Common Stock | 8,642 | $18.42 | $159,194 | ||
Sale | STEVENS DAVID B director | Common Stock | 43,134 | $18.47 | $796,814 |
| Quarter | Transcript |
|---|---|
| Q3 2022 5 Nov 2022 | Q3 2022 Earnings Call Transcript |
| Q2 2022 7 Aug 2022 | Q2 2022 Earnings Call Transcript |
| Q4 2021 25 Feb 2022 | Q4 2021 Earnings Call Transcript |
| Q3 2021 7 Nov 2021 | Q3 2021 Earnings Call Transcript |
Allscripts Healthcare Solutions: The Picture Is Improving
Definitive Healthcare: A Leader In Its Field, But Valuation Is Rich
Premier: Attractively Valued In An Important Market
R1 RCM: Undervalued Stock With 62.5% Upside
CareCloud: The (Cheap) King Of Healthcare SaaS
Allscripts Healthcare Solutions: A Mini Salesforce In Healthcare IT Making All The Right Moves
-
When is Veradigm's next earnings date?
Unfortunately, Veradigm's (MDRX) next earnings date is currently unknown.
-
Does Veradigm pay dividends?
No, Veradigm does not pay dividends.
-
How much money does Veradigm make?
Veradigm has a market capitalization of 1.02B.
-
What is Veradigm's stock symbol?
Veradigm Inc. is traded on the OTC under the ticker symbol "MDRX".
-
What is Veradigm's primary industry?
Company operates in the Healthcare sector and Medical - Healthcare Information Services industry.
-
How do i buy shares of Veradigm?
Shares of Veradigm can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Veradigm's key executives?
Veradigm's management team includes the following people:
- Mr. Paul M. Black Chief Executive Officer & Director(age: 67, pay: $2,770,000)
- Mr. Richard J. Poulton Pres & Chief Financial Officer(age: 60, pay: $1,920,000)
- Ms. Tejal Vakharia Senior Vice President and Gen. Counsel of Marketing & Gov. Affairs(age: 52, pay: $630,220)
-
How many employees does Veradigm have?
As Jul 2024, Veradigm employs 8,000 workers.
-
When Veradigm went public?
Veradigm Inc. is publicly traded company for more then 26 years since IPO on 26 Jul 1999.
-
What is Veradigm's official website?
The official website for Veradigm is veradigm.com.
-
Where are Veradigm's headquarters?
Veradigm is headquartered at 222 Merchandise Mart Plaza, Chicago, IL.
-
How can i contact Veradigm?
Veradigm's mailing address is 222 Merchandise Mart Plaza, Chicago, IL and company can be reached via phone at +800 3348534.
Veradigm company profile:
Veradigm Inc.
veradigm.comExchange:
OTC
Full time employees:
8,000
Industry:
Medical - Healthcare Information Services
Sector:
Healthcare
Veradigm Inc., a healthcare technology company, provides information technology solutions to healthcare providers, payers, and biopharma markets in the United States and internationally. The company offers solutions to healthcare providers, comprising Practice Management software, AI Patient Scheduling Software, and Electronic Statements and Payments; revenue cycle management solutions, including Revenue Cycle Services and revenue cycle management clearinghouse; electronic health records solutions, which include ePrescribe with EPCS, EHR software, Veradigm HER, and Practice Fusion HER; and Patient Engagement Platform. It also provides solutions to network partners, which comprise API connectivity solutions, such as Veradigm Connect, Veradigm App Expo, and Diagnostic Ordering and Resulting Network; Channel Partner Program; and Veradigm ePrescribe Enterprise. In addition, the company offers solutions to health plans and payers, comprising risk adjustment solutions, such as Health Equity Analytics, Risk Adjustment Analytics, Risk Mitigator, Comprehensive Submissions, and Utilization Analytics; quality management solutions, which include quality analytics and risk adjustment and quality management; data exchange+coding solutions, including eChart Courier, eChart Coder, and eChart Integration and Analytics; provider engagement and Veradigm Payer Insights; and Veradigm Payerpath solutions. Further, it provides solutions to biophama, including real world data solutions, such as real world and health data sets and cardiology and metabolic registries; real world evidence and Real World Evidence Analytics Platform; therapy focused solutions, such as cardiovascular, central nervous system, metabolic, and immunology data; and Digital Health Media solutions. The company was formerly known as Allscripts Healthcare Solutions, Inc. and changed its name to Veradigm Inc. in January 2023. Veradigm Inc. was founded in 1986 and is headquartered in Chicago, Illinois.
222 Merchandise Mart Plaza
Chicago, IL 60654
Chicago, IL 60654
CIK: 0001124804
ISIN: US01988P1084
CUSIP: 01988P108
